Bevacizumab is generally recommended for long-term use to improve the prognosis of patients, and the specific application needs to follow the doctor’s instructions. Bevacizumab is a commonly used targeted therapeutic drug for non-small cell lung cancer, metastatic colorectal cancer and other diseases, which can effectively inhibit the growth of tumors, improve the quality of life of patients, improve the prognosis of the disease, and prolong the survival time of patients. Bevacizumab needs to be used continuously until the tumor progresses, and the specific time of stopping the drug needs to be combined with one’s own specific situation under the doctor’s advice, and it is not recommended that patients stop the drug without authorization. Moreover, bleeding, gastrointestinal perforation and other adverse reactions may occur during the use of bevacizumab. It is recommended that patients use the drug under the guidance of a doctor.